The Drug Development Lifecycle Management

Key Takeaways

Now that we understand what clinical trials are and why they matter, let's zoom out and look at where they sit within the broader drug development life cycle. This will give you a mental map, a full picture of the journey a molecule takes from a laboratory bench to a patient's bedside. Drug development has five major stages. One, discovery. Two, preclinical. Three, clinical development, which is where our course is focused. Four, regulatory review and approval. And five, post marketing, sometimes called phase 4. The entire journey from early discovery to approval typically takes 10 to 15 years. It costs on average over $1 billion. And of all the compounds that enter pre-clinical testing, only about 1 in 10,000 will ever make it to market. It is a long, expensive, high-risk endeavor, which is why every successful approval is so significant. Drug development has five major stages. One, discovery. Two, preclinical. Three, clinical development, which is where our course is focused. Four, regulatory review and approval. And five, post marketing, sometimes called phase 4. The entire journey from early discovery to approval typically takes 10 to 15 years. It costs on average over $1 billion. And of all the compounds that enter pre-clinical testing, only about 1 in 10,000 will ever make it to market. It is a long, expensive, high-risk endeavor, which is why every successful approval is so significant. The journey begins in the discovery phase. Scientists identify a biological target, a protein, receptor, or enzyme that plays a role in a disease, and then screen thousands of chemical compounds to find one that interacts with that target in the desired way. The most promising compound then moves into pre-clinical testing, carried out first in cells and then in animals. The goal is to gather initial data on safety, toxicity, and how the body handles the drug. This stage typically takes 3 to 6 years. If the pre-clinical data is strong enough, the company can apply to begin testing in humans. In the US, this is done by submitting an investigational new drug application to the FDA. We'll cover the IND depth in section 5. If phase three is successful, the company submits a marketing authorization application. In the US, this is the NDA, the new drug application, or the BLA for biologics. In Europe, it is the MAA. These submissions can run to hundreds of thousands of pages of data. Regulators review the package and determine whether the benefit risk profile justifies approval. This review process typically takes 1 to two years and importantly approval is not the end of the story. Phase 4 or post marketing surveillance begins the moment a drug is on the market. Now that the drug is being used by millions of realworld patients including people who may not have been enrolled in the trials like the elderly or those with multiple conditions. Safety is monitored continuously. Some drugs require additional studies and in rare cases, drugs are withdrawn if post marketing data reveals risks that were not apparent in controlled trials. Before we move on, here's a knowledge check to test your understanding. A pharmaceutical company has completed pre-clinical testing on a promising new compound. They now want to test whether it is safe in humans for the very first time. What type of study is this and which phase does it belong to? The answer, this is an interventional clinical trial, specifically a phase one or first inhuman study. The primary objective of phase one is to establish safety and tolerability in humans, to determine what doses are acceptable, to understand how the body processes the drug, and to identify any early safety signals. Phase one studies are typically small, enrolling 20 to 80 participants, usually healthy volunteers. Though in therapeutic areas like oncology, patients with the target disease are often enrolled instead since the risk benefit calculation is different. Phase one does not aim to prove that the drug works. That comes later. Its job is simply to establish that it is safe enough to continue. To summarize lesson 1.3, drug development is a long staged and tightly regulated journey. Clinical trials sit at the center of it. They are the mechanism by which a promising compound becomes a medicine that doctors can prescribe with confidence. Understanding this life cycle gives you the context to understand why every step in a clinical trial matters so much. In the next section, we'll go deeper into the clinical phases, examining exactly what each phase is designed to achieve, who participates, and what success looks Like